The terms, per the grant. On October 17, 2023, Precigen was issued US11787848B2, covering CD33-specific chimeric antigen receptors. The CPC stack is rich in T-cell-receptor and signaling-domain tags — C07K 14/7051, 14/70517, 14/70521, 14/70575, 14/70578 — alongside the C07K 16/2803 binder, exposing the construct's modular design.
Why modularity matters to a teardown: a CAR's binder is target-specific (here, CD33, an acute-myeloid-leukemia antigen), but the hinge, transmembrane, and signaling domains are a reusable architecture deployable across many targets. The reusable layer is the platform asset; the binder is the program asset. Their royalty profiles differ.
The structure point: a deal on a modular CAR can be split into a target-specific license (the CD33 binder) and a platform license (the signaling architecture). For a model, the platform component is the higher-multiple, lower-variance asset because its royalty base grows with each new target built on the same backbone.
What the grant does not promise: a clinical result, an approval, or exclusivity over the broad CAR field. It is an exclusivity claim on a specific CD33-directed construct, within a crowded and modular design space.
The takeaway: in a cell-therapy term teardown, separate the reusable construct architecture from the target-specific binder and value them differently. Precigen's October 2023 CD33-CAR grant is a dated example of a modular construct whose value splits cleanly across those two layers.